GSK vs RGNX · P/E 13, $103.31B cap vs rev $114.4M
GlaxoSmithKline PLC ADR (GSK) versus Regenxbio Inc (RGNX) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Regenxbio Inc (RGNX) is a biotechnology company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported RGNX revenue for 2026-06-30 was $114.4M. Net income was -$67.3M. RGNX currently screens at market cap $440.4M.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. RGNX currently screens at market cap $440.4M.
Not investment advice. Open the GSK and RGNX stock pages for the full models.
Not investment advice.